Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget). Mazieres, J., Drilon, A. E., Mhanna, L., Milia, J., Lusque, A., Cortot, A. B., Mezquita, L., Thai, A., Couraud, S., Veillon, R., Mascaux, C., Schouten, R., Neal, J. W., Ng, T. L., Frueh, M., Peled, N., Gounant, V., Popat, S., Zhu, V., Gautschi, O. AMER SOC CLINICAL ONCOLOGY. 2018

View details for DOI 10.1200/JCO.2018.36.15_suppl.9010

View details for Web of Science ID 000442916003184